UiO:Life Science’s innovation programme SPARK Norway is designed to help academic innovators to advance promising research into value creating solutions. By applying a unique process model including mentoring, education, market exposure and global networks, SPARK Norway helps transforming good ideas into exceptional solutions.
On 9 and 10 June, NCMBM gathered at the Klækken Hotel in Hønefoss for two days of scientific talks, networking and community building.
The two-day retreat brought together around 80 participants to exchange knowledge, strengthen collaborations and connect with colleagues across the Centre.
A new study co-led by researchers at the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), and at the University of Helsinki has identified the protein SIT1 as a critical regulator of T cell activation and immune balance in humans. The findings, published in the Journal of Allergy and Clinical Immunology, provide important new insights into how the immune system is controlled and how disruptions in these mechanisms can contribute to immunodeficiency and cancer.
This study is the result of an international collaboration between researchers from Finland, Norway, Germany, and Austria.
The Nordic EMBL Partnership for Molecular Medicine has appointed Janna Saarela as its new Speaker, effective January 2026. Janna Saarela is the Director of the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM) and succeeds Oliver Billker from the Laboratory for Molecular Infection Medicine Sweden (MIMS) in representing the Partnership internationally.
ELIXIR has announced the life science data resources selected in its latest evaluation round for ELIXIR Core Data Resources (CDRs) and ELIXIR Deposition Databases.
Among the six newly approved Core Data Resources is JASPAR, a long-standing and widely used database for transcription factor binding profiles, with the work behind the resource currently led by Anthony Mathelier, Associate Director and Group Leader of the Computational Biology & Gene Regulation group at the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM).
A new era for motif resources
The team behind JASPAR, led by Anthony Mathelier at NCMBM, has released the 11th update. JASPAR is built and maintained by an international consortium of research groups, making it a global effort to support the genomics research landscape for studying how genes are regulated.
Inborn errors of immunity (IEIs) are a diverse group of more than 550 rare genetic disorders that disrupt how the immune system develops and functions. For patients, this can mean vulnerability to severe infections, autoimmunity, inflammatory diseases, or even cancer. Current treatment options are limited and often carry significant risks, leaving many families in search of safer and more precise therapies.
Researchers uncover how loss of a gene called MAP4K1 amplifies T cell responses, offering insights into immune disorders and potential therapies.
On the 3rd to 4th of June, NCMBM and Associate Investigators gathered at the Sundvolden Hotel near Oslo, for two days of scientific talks, networking, and community building.
The Better Therapies for Rare Immune Diseases group, led by Emma Haapaniemi, has been extended for a further 4 years, following its successful evaluation by NCMBM’s Scientific Advisory Board (SAB).
In November 2024, Damla Övek Baydar, a postdoctoral researcher in Anthony Mathelier’s group, went to the University of Stanford for research exchange supported by the early career researcher travel grant scheme of the UiO:Life Science Internationalisation support funds. Her stay initiated a collaboration with Anshul Kundaje’s world-leading lab in regulatory genomics and deep learning.
Frida Høsøien Haugen, PhD student in Emma Haapaniemi’s group, attended the EATRIS-organised 5-day comprehensive workshop on gene therapy innovation that took place in Leuven in November 2024.
The Kuijjer lab is expanding!
The importance of teamwork to develop better bioinformatics software.
The University of Oslo (UiO) is positioning itself as a leading player in interdisciplinary molecular medicine and bioscience research.
NCMM organised the 13th Nordic EMBL (European Molecular Biology Laboratory) Partnership meeting from September 16 to 19, 2024, and welcomed over 160 participants at Litteraturhuset in Oslo.
Accelerating early diagnosis and improving rare disease treatments through patient involvement
Marieke Kuijjer, Computational Biology and Systems Medicine Group leader, delivered a keynote lecture at the final Precision medicine at the Interface of Translational Science and Systems medicine (TranSYS) conference, in Belgrade, in June 2024.
NCMM’s engineers met to discuss the results of the ARK survey; the purpose of the meeting was two-fold, to reinforce cohesion across the research groups, and to explore ways of improving their work environment.
The Norwegian Bioinformatics Days 2024 were held in Bergen at the end of May 2024. The program offered talks, discussions, and workshops on topics such as genomics, diagnostic bioinformatics, machine learning, and molecular modelling.
On the 3rd to 4th of June, NCMM and Associate Investigators gathered at Oscarsborg in Oslo fjord, for two days of scientific talks and networking.
During his PhD, Lin Xue would spend hours at the microscope, observing the possible first steps of creating living cells on the early Earth.
The NCMM annual report for 2023 is now available online.
With a shared goal of implementing AI technology to propel molecular medicine research, NCMM and Simula Research Laboratory organized a joint seminar for the two to meet and identify possible synergies.
NCMM is pleased to announce the 7 projects that have received support as part of the NCMM Joint Postdoctoral Program in Molecular Life Science.
